In addition to treatment of NS, QRX003 is also being evaluated for pediatric NS and Peeling Skin Syndrome (PSS). Quoin has also advanced its QRX009 topical rapamycin platform, engaging with KOLs and advocacy foundations, and believes it is positioned to initiate clinical testing in multiple indications later in 2026, including an investigator study for Pachyonychia Congenita (PC), for which there are no approved treatments or cure. QNRX targets initiating this study in 3Q26, followed by subsequent investigator-led clinical studies in Gorlin Syndrome & Tuberous Sclerosis Complex. Designing assets to treat multiple indications potentially broadens their commercial prospects & scalability.
